The following information is disclosed in accordance with AIM Rule 26
| Business description | Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile. |
| Country of incorporation and main country of operation | Country of incorporation: England and Wales
Company registration number: 09818395 Main country of operation: UK |
| Current constitutional documents | Oncimmune’s current constitutional documents are available on the Company documents page |
| Details of other exchanges or trading platforms | Other than AIM, the Company’s shares are not admitted to or traded on any other exchanges or trading platforms. |
| Significant Shareholders and Shares in Issue | Please see our Shareholder analysis page for details |
| Restrictions on transfers of securities | There are no current restrictions on the transfer of Oncimmune’s AIM securities. |
| Annual Accounts | Oncimmune’s annual reports for the last three years are available on the Reports page |
| Regulatory news | Regulatory news announcements can be found on Oncimmune’s RNS news page |
| AIM admission document | Oncimmune’s most recent admission document is available on the Company documents page |
| Corporate governance | The Board has adopted the 2018 Quoted Companies Alliance Corporate Governance Code (the “QCA Code”) as the basis of the Group’s governance framework. More information about how we apply the QCA code is available on the Governance page |
| Directors’ names and biographies | The names, responsibilities and a brief biography of each member of the Board of Directors, including committee membership, is available on the Board page |
| Board of Directors Committees | Details of the Committees of Oncimmune’s Board of Directors and their responsibilities are described on the Governance page |
| UK City Code on Takeovers and Mergers | Oncimmune Holdings Plc is subject to the UK City Code on Takeovers and Mergers. |
| Company advisers | Details of Oncimmune’s Nominated Advisor and other key key advisors are available on Advisors page |
Last reviewed: 24th April 2024